Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
Clinical trial NCT03382899 · TERMINATED
Trial details
- NCT number
- NCT03382899
- Sponsor
- Eli Lilly and Company
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-19
- Primary completion
- 2019-12-06
- Enrollment
- 101
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.